Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 12/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14370134 | 0.76 | ACHE (0.39) | ACHETSHRMAPTMEN1KMT2A | |
| SCHEMBL27701976 | 0.75 | MEN1 (0.40) | MAPK1NSD2ACHEMAPTMEN1 | |
| SCHEMBL30421875 | 0.72 | P2RX7 (0.34) | MEN1KMT2A | |
| SCHEMBL3884942 | 0.70 | ACHE (0.56) | MAPK1NSD2ACHETSHRMAPT | |
| SCHEMBL6701780 | 0.69 | ACHE (0.40) | MAPK1ACHETSHRMAPTMEN1 | |
| SCHEMBL31539787 | 0.68 | TSHR (0.39) | MAPK1TSHRMAPT | |
| SCHEMBL2708394 | 0.68 | ACHE (0.56) | MAPK1NSD2ACHETSHRMAPT | |
| SCHEMBL6492773 | 0.68 | POLB (0.48) | MAPK1NSD2ACHETSHRMAPT | |
| SCHEMBL6494851 | 0.68 | MAPK1 (0.43) | MAPK1NSD2ACHEMAPTMEN1 | |
| SCHEMBL6956277 | 0.68 | ACHE (0.40) | MAPK1ACHETSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114364677-B | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11976064-B2 | Toll-like receptor agonists | PFIZER INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20220274986-A1 | TOLL-LIKE RECEPTOR AGONISTS | PFIZER INC. (US) | 2022-09-01 | — | — | US | disclosed |
| EP-3999507-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONISTS | Pfizer Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11339159-B2 | Toll-like receptor agonists | PFIZER INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114364677-A | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021009676-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONSITS | PFIZER INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20210017172-A1 | TOLL-LIKE RECEPTOR AGONISTS | PFIZER INC. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-1789042-B1 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-05-02 | — | — | EP | disclosed |
| US-7579359-B2 | 1-alkoxy 1H-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2006028962-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1605943-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2004080398-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-6664260-B2 | Viricides; anticarcinogneic agents; induction cytokine biosynthesis | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| EP-1339715-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | MAPK1 1368/4885NSD2 923/4885ACHE 4670/4885 |
| US-11976064-B2 | Toll-like receptor agonists | TLR3, TLR1, TLR4 | MAPK1 666/4885NSD2 3286/4885ACHE 4885/4885 |
| US-20210017172-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR3, TLR1, TLR4 | MAPK1 666/4885NSD2 3286/4885ACHE 4885/4885 |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | MAPK1 1790/4885NSD2 2114/4885ACHE 4209/4885 |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | MAPK1 1790/4885NSD2 2114/4885ACHE 4209/4885 |
| US-11339159-B2 | Toll-like receptor agonists | TLR3, TLR1, TLR4 | MAPK1 666/4885NSD2 3286/4885ACHE 4885/4885 |
| US-20220274986-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR3, TLR1, TLR4 | MAPK1 666/4885NSD2 3286/4885ACHE 4885/4885 |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | MAPK1 1368/4885NSD2 923/4885ACHE 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.